Conference Details - Overview

View all Conferences

Continuing Education Information

Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is approved for AMA PRA Category 1 Credit™

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.

Current Trends in Lung and Head & Neck Cancer

Specific Time and Location Information

Select a time and location below to be directed to specific details relating to this conference:

Please select:

Conference Overview

The 2010 Current Trends in Lung and Head & Neck Cancer series offers physicians the opportunity to learn about the current standards of care as well as the latest developments in lung and head & neck cancer treatments, including findings presented at recent major oncology conferences. Interactive case discussions will enhance the learning experience and foster the integration of evidence-based patient care into everyday community practice. This educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with lung and head & neck cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung and head & neck cancer are also invited to attend.

At the conclusion of this symposium, you should be able to:

  • Assess the role of tumor histology and biomarkers in formulating a personalized therapy for patients with lung cancer
  • Describe differential responses to therapy in patients with head and neck cancer and HPV-positive tumors
  • Discuss neoadjuvant and adjuvant chemotherapy in early-stage lung cancer
  • Evaluate treatment options under investigation for combined modality therapy of stage III NSCLC
  • Describe the efficacy and safety of concurrent chemoradiation for patients with LD-SCLC
  • Assess the efficacy and safety of targeted agents and/or induction regimens for locally advanced head and neck cancer
  • Evaluate approaches to optimize the integration of targeted agents into treatment of metastatic NSCLC
  • Describe the role of maintenance therapy with cytotoxic or targeted agents in lung cancer
  • Apply data from clinical trials to determine the optimal course of therapy in defined patient populations

Educational Grants

An educational grant for this activity was provided by:


  1. Genentech BioOncology/OSI Oncology
  2. Lilly USA, LLC